PPIDT00091
Drug Information
| Name | Bevacizumab |
|---|---|
| Sequence | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB00112 |
| Type | biotech |
| Indication | As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.[L12648,L39233,L41514,L43130,L43302,L49826] Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).[L12699] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution, concentrate | Intravenous |
2500000 mg
|
| Solution | Intravenous |
100 mg/4ml
|
| Solution | Intravenous |
400 mg/16ml
|
| Injection | Intravenous |
25 mg
|
| Injection, solution, concentrate | Intravenous; Parenteral |
100 mg/4ml
|
| Injection, solution, concentrate | Intravenous; Parenteral |
400 mg/16ml
|
| Solution | Intravenous |
25 mg / mL
|
| Solution | Intravenous |
400.000 mg
|
| Solution | Intravenous |
25 mg
|
| Injection | Intravenous |
|
| Injection | Intravenous |
25 MG/ML
|
| Solution, concentrate | Intravenous |
400 mg
|
| Solution, concentrate | Intravenous |
40000000 mg
|
| Solution, concentrate | Intravenous |
10000000 mg
|
| Injection, solution, concentrate | Intravenous |
25 MG/ML
|
| Injection, solution, concentrate | Intravenous |
25 mg/1ml
|
| Injection, solution | Intravitreal |
25 mg/ml
|
| Solution | Intravenous |
100.000 mg
|
| Injection, solution | Intravenous |
100 mg/4mL
|
| Injection, solution | Intravenous |
400 mg/16mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
25 MG/ML
|
| Solution | Intravenous |
100.00 mg
|
| Injection, solution, concentrate | — |
100 mg/4ml
|
| Injection, solution, concentrate | — |
400 mg/16ml
|
| Injection, solution | Intravenous |
25 mg/ml
|
| Solution | Intravenous |
25 mg/mL
|
| Solution | Intravenous |
2500000 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg/4ml
|
| Injection, solution, concentrate | Intravenous |
400 mg/16ml
|
| Solution | Intravenous |
100 mg / 4 mL
|
| Solution | Intravenous |
400 mg / 16 mL
|
| Injection | Intravenous |
100 mg/4ml
|
| Injection | Intravenous |
400 mg/16ml
|
| Solution | Intravenous |
100 mg
|
| Solution | Intravenous |
400 mg
|
| Solution, concentrate | Intravenous |
25 mg
|
| Solution | Intravenous |
25 mg/1ml
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P15692 | VEGFA | Vascular endothelial growth factor A, long form | Homo sapiens | inhibitor | Link |
| target | P02745 | C1QA | Complement C1q subcomponent subunit A | Homo sapiens | unknown | Link |
| target | P02746 | C1QB | Complement C1q subcomponent subunit B | Homo sapiens | unknown | Link |
| target | P02747 | C1QC | Complement C1q subcomponent subunit C | Homo sapiens | unknown | Link |
| target | P08637 | FCGR3A | Low affinity immunoglobulin gamma Fc region receptor III-A | Homo sapiens | unknown | Link |
| target | P12314 | FCGR1A | High affinity immunoglobulin gamma Fc receptor I | Homo sapiens | unknown | Link |
| target | P12318 | FCGR2A | Low affinity immunoglobulin gamma Fc region receptor II-a | Homo sapiens | unknown | Link |
| target | P31994 | FCGR2B | Low affinity immunoglobulin gamma Fc region receptor II-b | Homo sapiens | unknown | Link |
| target | P31995 | FCGR2C | Low affinity immunoglobulin gamma Fc region receptor II-c | Homo sapiens | unknown | Link |